Supplementary Appendix from Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing

Le résumé fourni par la source

Supplementary Appendix: Additional methods. Carfilzomib-treated patients - Trial design; Table S1. List and classification method of the analyzed variables; Table S2. Induction treatment classification; Table S3. List of the 21 genes analyzed and mutation frequency; Table S4. Distribution of upfront treatment and ASCT in CT subgroups; Table S5. Distribution of variables in Early PD vs reference population; Figure S1. Multivariate logistic regression model evaluating risk factors associated with death within 24 months; Figure S2. Sub-analysis on patients with or without baseline del(17p) and/or TP53 mutation; Figure S3. TP53 and IGLL5 mutations at diagnosis and at first relapse in available longitudinal samples; Figure S4. Epanechnikov kernel-smoothed estimated hazard rates of progressive disease (PD) over time; Figure S5. Comparison of Seq-FISH and conventional FISH in a subgroup of patients enrolled in clinical trials and analyzed in the same centralized laboratory.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.